Report cover image

Japan CRISPR-Cas9 Gene Editing Market - 2024-2033

Publisher DataM Intelligence 4Market Research LLP
Published Mar 02, 2026
Length 180 Pages
SKU # DTAM21122368

Description

Japan CRISPR-Cas9 Gene Editing Market Overview:
The Japan CRISPR-Cas9 Gene Editing Market was valued at US$ 232.3 Million in 2024 and is anticipated to reach US$ 856.4 Million by 2033, at a CAGR of 0.156 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Japan CRISPR-Cas9 Gene Editing Market.

This report delivers a comprehensive overview of the Japan CRISPR-Cas9 Gene Editing Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Japan CRISPR-Cas9 Gene Editing Market. The Japan CRISPR-Cas9 Gene Editing Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Japan CRISPR-Cas9 Gene Editing Market Scope:
By Product
• CRISPR-Cas9 Reagents
• Instruments & Systems
• Software & Platforms

By Technology
• CRISPR-Cas9 Nuclease Editing
• CRISPR Interference (CRISPRi)
• CRISPR Activation (CRISPRa)
• Base Editing
• Others

By End User
• Pharmaceutical & Biotechnology Companies
• Academic & Government Research Institutes
• Clinical Research Organizations
• Contract Research Organizations (CROs)
• Hospitals & Diagnostic Centers
• Agricultural & Food Biotechnology Firms

By Application
• Drug Discovery & Development
• Functional Genomics
• Gene Therapy Research
• Cell Line Engineering
• Disease Modeling
• Agricultural Biotechnology
• Diagnostics & Biomarker Development
• Others

By Delivery Method
• Viral Systems
• Non-viral Systems

By Disease Area
• Oncology
• Genetic Disorders
• Infectious Diseases
• Cardiovascular & Metabolic Disorders
• Neurological Diseases
• Others

Key Players
• Takeda Pharmaceutical Company Limited
• DAIICHI SANKYO COMPANY, LIMITED
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Takara Bio Inc.
• DH Life Sciences, LLC.
• GenScript
• Sumitomo Chemical Co., Ltd.
• Astellas Pharma Inc.
• Illumina, Inc.

Major Highlights
This report delivers a comprehensive overview of the Japan CRISPR-Cas9 Gene Editing Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Japan CRISPR-Cas9 Gene Editing Market. The Japan CRISPR-Cas9 Gene Editing Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

180 Pages
1. Definition and Overview
1.1. Study Objectives
1.2. Market Definition
1.3. Market Scope
1.4. Stakeholder Analysis
1.5. Currency Considered
1.6. Study Period
2. Executive Summary
2.1. Key Takeaways
2.2. Top To Bottom Analysis
2.3. Market Share Analysis
2.4. Data Points from Key Primary Interviews
2.5. Data Points from Key Secondary Databases
2.6. Market Snapshot
2.7. Geographical Snapshot
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Increasing investments in precision medicine and genomic research in Japan
3.1.1.2. Growing adoption of CRISPR technology in drug discovery and pharmaceutical R&D
3.1.1.3. Government and institutional funding support for advanced biotechnology innovation
3.1.2. Restraints
3.1.2.1. High cost of CRISPR technology development and implementation
3.1.2.2. Ethical concerns and strict regulatory approvals for gene editing research
3.1.3. Opportunity
3.1.3.1. Rising demand for gene therapy and personalized medicine applications
3.1.3.2. Expansion of biotech collaborations between academic institutions and pharma companies
3.1.3.3. Increasing research focus on rare genetic diseases and oncology treatments
3.1.4. Trends
3.1.4.1. Development of next-generation CRISPR technologies, such as base and prime editing
3.1.4.2. Growing integration of artificial intelligence and bioinformatics in genome editing workflows
3.1.5. Impact Analysis
4. Industry Analysis
4.1. Porter's Five Force Analysis – Japan CRISPR-Cas9 Gene Editing Market
4.2. Geopolitical & Supply Chain Exposure
4.3. Social & Patient-Centric Factors
4.4. Economic Factors
4.5. Pricing Analysis
4.6. Regulatory Analysis
4.7. Go-To-Market (GTM) Strategy
4.8. Innovation & R&D Trends
4.9. Sustainability and ESG Analysis
4.10. Healthcare & Gene Therapy Ecosystem Participants
4.11. Buyer Decision Criteria & Adoption Drivers
4.12. DMI Opinion – Strategic Outlook for the Japan CRISPR-Cas9 Gene Editing Market
5. By Product
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
5.1.2. Market Attractiveness Index, By Product
5.2. CRISPR-Cas9 Reagents*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.2.3. Cas9 Enzymes
5.2.4. Guide RNAs
5.2.5. Vectors & Plasmids
5.2.6. Buffers & Kits
5.3. Instruments & Systems
5.3.1. PCR Systems
5.3.2. Electroporators
5.3.3. Microinjection Systems
5.3.4. Flow Cytometers
5.4. Software & Platforms
5.4.1. Bioinformatics & Design Tools
5.4.2. Data Analysis Software
6. By Technology
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
6.1.2. Market Attractiveness Index, By Technology
6.2. CRISPR-Cas9 Nuclease Editing*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. CRISPR Interference (CRISPRi)
6.4. CRISPR Activation (CRISPRa)
6.5. Base Editing
6.6. Others
7. By End User
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
7.1.2. Market Attractiveness Index, By End User
7.2. Pharmaceutical & Biotechnology Companies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Academic & Government Research Institutes
7.4. Clinical Research Organizations
7.5. Contract Research Organizations (CROs)
7.6. Hospitals & Diagnostic Centers
7.7. Agricultural & Food Biotechnology Firms
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Drug Discovery & Development*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Functional Genomics
8.4. Gene Therapy Research
8.5. Cell Line Engineering
8.6. Disease Modeling
8.7. Agricultural Biotechnology
8.8. Diagnostics & Biomarker Development
8.9. Others
9. By Delivery Method
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Method
9.1.2. Market Attractiveness Index, By Delivery Method
9.2. Viral Systems*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.3. Lentiviral
9.2.4. Adenoviral
9.3. Non-viral Systems
9.3.1. Electroporation
9.3.2. Lipid Nanoparticles
9.3.3. Physical Methods
10. By Disease Area
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area
10.1.2. Market Attractiveness Index, By Disease Area
10.2. Oncology*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Genetic Disorders
10.4. Infectious Diseases
10.5. Cardiovascular & Metabolic Disorders
10.6. Neurological Diseases
10.7. Others
11. Competitive Landscape Analysis
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
11.4. Partner Identification Analysis
11.5. Investment & Funding Landscape
11.6. Strategic Alliances & Innovation Pipelines
12. Company Profiles
12.1. Takeda Pharmaceutical Company Limited*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.3. Revenue Analysis
12.1.4. Pricing Analysis
12.1.5. SWOT Analysis
12.1.6. Recent Developments
12.1.6.1. Major Deals
12.1.6.2. M&A
12.1.6.3. Collaboration
12.1.6.4. Acquisition
12.1.6.5. Joint Ventures
12.1.6.6. Innovations
12.1.7. Recent News
12.1.7.1. Events
12.1.7.2. Conferences
12.1.7.3. Symposiums
12.1.7.4. Webinars
12.2. DAIICHI SANKYO COMPANY, LIMITED
12.3. Thermo Fisher Scientific Inc.
12.4. Merck KGaA
12.5. Takara Bio Inc.
12.6. DH Life Sciences, LLC.
12.7. GenScript
12.8. Sumitomo Chemical Co., Ltd.
12.9. Astellas Pharma Inc.
12.10. Illumina, Inc. (LIST NOT EXHAUSTIVE )
13. Japan CRISPR-Cas9 Gene Editing Market – Research Methodology
13.1. Research Data
13.1.1. Secondary Data
13.1.2. Primary Data
13.1.3. CAGR Analysis
13.2. Market Size Estimation Methodology
13.2.1. Bottom-Up Approach
13.2.2. Top-Down Approach
13.3. Market Breakdown & Data Triangulation
13.4. Research Assumptions
13.5. Limitations
14. Appendix
14.1. About Us and Services
14.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us